Long-term outcomes of COVID-19 convalescents: An 18.5-month longitudinal study in Wuhan

Int J Infect Dis. 2023 Feb:127:85-92. doi: 10.1016/j.ijid.2022.12.008. Epub 2022 Dec 9.

Abstract

Objectives: This study aimed to describe the full scope of long-term outcomes and the ongoing pathophysiological alterations among COVID-19 survivors.

Methods: We established a longitudinal cohort of 208 COVID-19 convalescents and followed them at 3.3 (interquartile range [IQR]: 1.3, 4.4, visit 1), 9.2 (IQR: 9.0, 9.6, visit 2), and 18.5 (IQR: 18.2, 19.1, visit 3) months after infection, respectively. Serial changes in multiple physical and psychological outcomes were comprehensively characterized. We, in addition, explored the potential risk factors of SARS-CoV-2 antibody response and sequelae symptoms.

Results: We observed continuous improvement of sequelae symptoms, lung function, chest computed tomography (CT), 6-minute walk test, and the Borg dyspnea scale, whereas sequelae symptoms (at least one) and abnormal chest CT patterns still existed in 45.2% and about 30% of participants at 18.5 months, respectively. Anxiety and depression disorders were alleviated for the convalescents, although depression status was sustained for a longer duration.

Conclusions: Most COVID-19 convalescents had an overall improved physical and psychological health status, whereas sequelae symptoms, residual lesions on lung function, exercise impairment, and mental health disorders were still observed in a small proportion of participants at 18.5 months after infection. Implementing appropriate preventive and management strategies for the ever-growing COVID-19 population is warranted.

Keywords: COVID-19; CT abnormalities; Depression and anxiety; Longitudinal cohort; Lung function; Sequelae.

MeSH terms

  • Antibodies, Viral
  • Anxiety / epidemiology
  • COVID-19*
  • Disease Progression
  • Humans
  • Longitudinal Studies
  • SARS-CoV-2

Substances

  • Antibodies, Viral